Abstract | OBJECTIVE: METHODS: The expression of DSC1-3 mRNAs was analysed by RT-PCR. The methylation status of DSCs was analysed by demethylation tests and bisulphite sequencing. Protein expression of DSCs in primary lung cancer was evaluated by immunohistochemistry on tissue microarrays. RESULTS: DSC1-3 mRNAs were downregulated in lung cancer cells, and the expression was restored in four out of seven cell lines, respectively, after 5-aza-2'-deoxycytidine treatment. A heterogeneous methylation pattern was detected by bisulphite sequencing in exon 1 of DSC2 and DSC3. In 199 patients with primary lung cancer, we found that lower protein expression of DSC1 was significantly linked to worse tumour differentiation (p=0.017), DSC3 proteins were more expressed in squamous cell carcinoma (SCC) compared with adenocarcinoma (ADC) (p<0.001), and reduced expression of DSC1 and DSC3 was significantly correlated with poor clinical outcome (p=0.045 and p=0.007, respectively). CONCLUSIONS: Our data suggest that downregulation of DSC1-3 may be explained by DNA methylation, DSC1 may be a marker for tumour differentiation, DSC3 has a potential diagnostic value in subclassification of non-small cell lung carcinoma into SCC and ADC, and furthermore, DSC1 and DSC3 may be prognostic markers for lung cancer.
|
Authors | Tiantian Cui, Yuan Chen, Linlin Yang, Masoud Mireskandari, Thomas Knösel, Qing Zhang, Lukas Herbert Kohler, Almut Kunze, Norbert Presselt, Iver Petersen |
Journal | Journal of clinical pathology
(J Clin Pathol)
Vol. 65
Issue 12
Pg. 1100-6
(Dec 2012)
ISSN: 1472-4146 [Electronic] England |
PMID | 23002285
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Carcinoma
(diagnosis, metabolism, pathology)
- Cell Line, Tumor
- Desmocollins
(metabolism)
- Down-Regulation
- Humans
- Lung Neoplasms
(diagnosis, metabolism, pathology)
- Neoplasm Staging
- Prognosis
|